Skip to main content

HOMEOSTASIS DE PROTEINAS EN EL DESARROLLO Y LA ENFERMEDAD: INTERACCION DE FACTORES UBIQUITINA-LIKE Y SALL EN CILIOGENESIS

PID2020-114178GB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells

  • Seoane, Rocío
  • Lama-Díaz, Tomás
  • Romero, Antonia María
  • El Motiam, Ahmed
  • Vidal, Santiago
  • Bouzaher, Yanis H.
  • Blanquer, María
  • Tolosa, Rocío M.
  • Castillo Mewa, Juan
  • Rodríguez, Manuel S.
  • García-Sastre, Adolfo
  • Xirodimas, Dimitris
  • Sutherland, James D.
  • Barrio, Rosa
  • Alepuz, Paula
  • Blanco, Miguel G.
  • Farràs, Rosa
  • Rivas, Carmen
  • Martínez-Férriz, Arantxa|||0000-0001-7193-2575
[EN] BackgroundThe eukaryotic translation initiation protein eIF5A is a highly conserved and essential factor that plays a critical role in different physiological and pathological processes including stress response and cancer. Different proteomic studies suggest that eIF5A may be a small ubiquitin-like modifier (SUMO) substrate, but whether eIF5A is indeed SUMOylated and how relevant is this modification for eIF5A activities are still unknown.MethodsSUMOylation was evaluated using in vitro SUMOylation assays, Histidine-tagged proteins purification from His6-SUMO2 transfected cells, and isolation of endogenously SUMOylated proteins using SUMO-binding entities (SUBES). Mutants were engineered by site-directed mutagenesis. Protein stability was measured by a cycloheximide chase assay. Protein localization was determined using immunofluorescence and cellular fractionation assays. The ability of eIF5A1 constructs to complement the growth of Saccharomyces cerevisiae strains harboring thermosensitive mutants of a yeast EIF5A homolog gene (HYP2) was analyzed. The polysome profile and the formation of stress granules in cells expressing Pab1-GFP (a stress granule marker) by immunofluorescence were determined in yeast cells subjected to heat shock. Cell growth and migration of pancreatic ductal adenocarcinoma PANC-1 cells overexpressing different eIF5A1 constructs were evaluated using crystal violet staining and transwell inserts, respectively. Statistical analysis was performed with GraphPad Software, using unpaired Student's t-test, or one-way or two-way analysis of variance (ANOVA).ResultsWe found that eIF5A is modified by SUMO2 in vitro, in transfected cells and under endogenous conditions, revealing its physiological relevance. We identified several SUMO sites in eIF5A and found that SUMOylation modulates both the stability and the localization of eIF5A in mammalian cells. Interestingly, the SUMOylation of eIF5A responds to specific stresses, indicating that it is a regulated process. SUMOylation of eIF5A is conserved in yeast, the eIF5A SUMOylation mutants are unable to completely suppress the defects of HYP2 mutants, and SUMOylation of eIF5A is important for both stress granules formation and disassembly of polysomes induced by heat-shock. Moreover, mutation of the SUMOylation sites in eIF5A abolishes its promigratory and proproliferative activities in PANC-1 cells.ConclusionsSUMO2 conjugation to eIF5A is a stress-induced response implicated in the adaptation of yeast cells to heat-shock stress and required to promote the growth and migration of pancreatic ductal adenocarcinoma cells., Open Access funding was provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding at the laboratory of CR is provided by the Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P, PID2021-126510NBI00), and by the Xunta de Galicia (ED431G 2023/10). RS, SV and TLD are predoctoral fellows funded by the Xunta de Galicia – Consellería de Cultura, Educación y Ordenación Universitaria (ED481A-2020/160, ED481A-2018/110, and ED481A-2018/042, respectively). AMR is a postdoctoral fellow funded by the Generalitat Valenciana (CIAPOS2021/117). MB is a predoctoral fellow funded by Banco Santander and the University of Santiago de Compostela. RMT is a predoctoral fellow funded by the Instituto de Investigación Sanitaria de Santiago de Compostela. The Blanco lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-115472GB-I00) and by the Xunta de Galicia/FEDER – Una manera de hacer Europa (ED431C 2019/013). The RF lab is supported by the Fondo de Investigación Sanitaria, ISCIII (PI20-00194). The PA lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-120066RB-I00) and by GVA CIAICO/2022/237. AMF is a predoctoral fellow funded by the Asociación Española Contra el Cáncer (AECC APRO 2018). RB and JDS thank MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-114178GB-I00, CEX2021-001136-S). Finally, CR, RF and RB acknowledge support from SAF2017-90900-REDT (UBIRed Program, Spain) and COST Action ProteoCure CA20113.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells

  • Seoane, Rocío
  • Lama-Díaz, Tomás
  • Romero, Antonia María
  • El Motiam, Ahmed
  • Martínez-Férriz, Arantxa
  • Vidal, Santiago
  • Bouzaher, Yanis H.
  • Blanquer, María
  • Tolosa, Rocío M.
  • Castillo Mewa, Juan
  • Álvarez-Rodríguez, Manuel
  • García-Sastre, Adolfo
  • Xirodimas, Dimitris
  • Sutherland, James D.
  • Barrio, Rosa
  • Alepuz, Paula
  • Blanco, Miguel G.
  • Farràs, Rosa
  • Rivas, Carmen
The eukaryotic translation initiation protein eIF5A is a highly conserved and essential factor that plays a critical role in different physiological and pathological processes including stress response and cancer. Different proteomic studies suggest that eIF5A may be a small ubiquitin-like modifier (SUMO) substrate, but whether eIF5A is indeed SUMOylated and how relevant is this modification for eIF5A activities are still unknown., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding at the laboratory of CR is provided by Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P), (PID2021-126510NB-I00), and Xunta de Galicia (ED431G 2023/10). RS, SV and TLD are predoctoral fellows funded by Xunta de Galicia-Consellería de Cultura, Educación y Ordenación Universitaria (ED481A-2020/160, ED481A-2018/110, and ED481A-2018/042, respectively). AMR is a postdoctoral funded by Generalitat Valenciana (CIAPOS2021/117). MB is a predoctoral fellow funded by Banco Santander and University of Santiago de Compostela. RMT is a predoctoral fellow funded by Instituto de Investigación Sanitaria de Santiago de Compostela. The Blanco lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 [PID2020-115472 GB-I00] and Xunta de Galicia/ FEDER ‘Una manera de hacer Europa’ [ED431C 2019/013]. RF lab is supported by Fondo de Investigación Sanitaria, ISCIII (PI20-00194). PA lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-120066RB-I00) and by GVA CIAICO/2022/237. AMF is a predoctoral fellow funded by Asociación Española Contra el Cáncer (AECC APRO 2018). RB and JDS thank MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-114178 GB-I00, CEX2021-001136-S). CR, RF and RB acknowledge SAF2017-90900-REDT support (UBIRed Program, Spain) and COST Action ProteoCure CA20113., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

  • El Motiam, Ahmed
  • Bouzaher, Yanis H
  • Chen, Haifen
  • Seoane, Rocío
  • Vidal, Santiago
  • Blanquer, María
  • Tolosa, Rocío M
  • Rodríguez-Lemus, Beatriz
  • Herrera-Gavilán, José A
  • Vidal, Anxo
  • Palmero, Ignacio
  • Rodríguez, Manuel S.
  • Sutherland, James D
  • Barrio, Rosa
  • Xirodimas, Dimitris
  • Collado, Manuel
  • Bremner, Rod
  • Rivas, Carmen
p14ARF is a lysine-less tumor suppressor that enhances SUMOylation of its interactors. Although p14ARF is known to interact with the E2 SUMO conjugating enzyme UBC9, the link between ARF and SUMOylation is poorly understood and the potential impact of SUMOylation on p14ARF is unknown. Here we show that SUMO2 conjugates to the N-terminus of p14ARF and stabilizes it. Either depleting UBC9 or pharmacologically inhibiting SUMOylation, induces p14ARF degradation. In contrast, blocking ubiquitination or NEDDylation, with TAK-243 or MLN4924/Pevonedistat respectively, increases p14ARF SUMOylation and restores p14ARF levels when SUMOylation is blocked. Treatment with MLN4924 also causes p14ARF-dependent mRNA upregulation of the SUMOylation components SUMO1, SUMO2, and UBC9, globally augmenting SUMOylation. Finally, p14ARF contributes to MLN4924-driven cytotoxicity of prostate cancer cells. Our results provide evidence that, despite lacking lysine, p14ARF is SUMOylated and this modification is critical to counter ubiquitin driven degradation and establishes a new link between inhibition of NEDDylation and SUMOylation., Funding at the laboratory of CR is provided by Ministry of Science, Innovation and Universities and FEDER (PID2021-126510NB-I00), and Xunta de Galicia/ FEDER “Una manera de hacer Europa” (ED431G 2023/10). MB is a predoctoral fellow funded by Banco Santander and University of Santiago de Compostela. RMT is a predoctoral fellow funded by Instituto de Investigación Sanitaria de Santiago de Compostela. BRL is a predoctoral fellow funded by Asociación Española Contra el Cáncer (AECC). JAHG is funded by FPU grant from Ministry of Science and Innovation (MCIN), Spain (FPU23/00271). CR, MSR, JDC, DX, and RB acknowledge COST Action ProteoCure CA20113. RB and JDS acknowledge MCIN/AEI/10.13039/501100011033 (projects PID2023-147399NB-I00 and PID2020-114178GB-I00). IP lab is funded by PID2021-122600OB-I0., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Pujana-Vaquerizo, Mikel
  • Martínez-Laosa, Belén
  • Ponce-Rodríguez, María
  • García-Longarte, Saioa
  • Mendizabal, Isabel
  • Gimeno, Ana
  • Rogalska, Malgorzata
  • Tan, Joycelyn
  • Cabrera, Diana
  • van Liempd, Sebastiaan
  • Ximenez-Embun, Pilar
  • Espinosa, Sergio
  • Fagoaga-Eugui, Maider
  • Peccati, Francesca
  • Zakrzewski, Maciej
  • Astobiza, Ianire
  • Arana-Castañares, Mikel
  • Cherkaoui, Sarah
  • Sendino, Maria
  • Martín-Barros, Inés
  • Ercilla, Amaia
  • Bozal-Basterra, Laura
  • Carlevaris, Onintza
  • Arruabarrena-Aristorena, Amaia
  • Pérez-Andrés, Encarnación
  • Santamaria-Zamorano, Telmo
  • Ferrer-Bonsoms, Juan A.
  • Carazo, Fernando
  • Ciesla, Maciej
  • Lobato, Cesar
  • Seoane, Joan
  • Martín-Martín, Natalia
  • Barrio, Rosa
  • Sutherland, James D.
  • Aransay, Ana M.
  • Falcón-Pérez, Juan Manuel
  • Martínez-Pastor, Barbara
  • Rubio, Angel
  • Blanco, Francisco J.
  • Hogarty, Michael D.
  • Morscher, Raphael J.
  • Berra, Edurne
  • Serwa, Remigiusz A.
  • Jiménez-Barbero, Jesús
  • Jiménez-Osés, Gonzalo
  • Efeyan, Alejo
  • Finley, Lydia
  • Lizcano, Jose M.
  • Muñoz, Javier
  • Valcarcel, Juan
  • Carracedo, Arkaitz
40 páginas, figuras y material suplementario., Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).